NCT00989092View on ClinicalTrials.gov

Darbepoetin Alfa and Anemia of Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

287

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

January 31, 2004

Study Completion Date

June 30, 2004

Conditions
AnemiaAnemia of CancerCancerCarcinomaNeoplasmsNon-Myeloid Malignancies
Interventions
BIOLOGICAL

darbepoetin alfa

Administered subcutaneously.

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00989092 - Darbepoetin Alfa and Anemia of Cancer | Biotech Hunter | Biotech Hunter